Thus, the expression level of TTF1 did not significantly affect the efficacy of pembrolizumab monotherapy or chemoimmunotherapy in PD-L1 high-expressing patients with non-Sq NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.